HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Koller, W. C. Articles by Herbster, G. Search for Related Content PubMed PubMed Citation Articles by Koller, W. C. Articles by Herbster, G.

Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease

Department of Neurology, Loyola University School of Medicine, Hines VA Hospital, Chicago, IL.

Terguride, an analogue of lisuride, decreased locomotor activity, produced cataplexy, and blocked apomorphine-induced stereotypic behavior. It did not induce stereotypies in rodents or emesis in dogs. However, in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra, terguride produced contralateral rotation. Terguride bound to D-2 striatal dopamine receptors. Terguride has both agonist and antagonist actions at striatal dopamine receptors, but chronic administration did not produce behavioral supersensitivity. These pharmacologic properties differ from those of other antiparkinsonian agents; terguride maybe effective for the chronic treatment of Parkinson's disease.

Address correspondence and reprint requests to Dr. Koller. Neurology Service (127), Hines VA Hospital, Hines, IL 60141.

Supported by the Veterans Administration.

Received May 12, 1986. Accepted for publication in final form August 5, 1986.